Core Points - Pharma Equity Group A/S held its Annual General Meeting on April 16, 2025, where various proposals were discussed and adopted [1][6] Group 1: Board of Directors' Report - The former CEO, Thomas Kaas Selsø, presented the Board's report on the Company's activities over the past year, addressing shareholder questions regarding the Market Maker agreement with Danske Bank and the potential delisting from Nasdaq Copenhagen [3][4] - Shareholders expressed concerns about the declining share price, attributing it to large shareholders selling their shares, while also acknowledging the Company's successful financing in 2024 and positive research results [4][5] Group 2: Financial Proposals - The audited 2023 annual report was presented, and the discharge of the Board and Executive Management was proposed, with no objections raised from shareholders [8][11] - The expected revenue for the current financial year was projected at DKK 11 million, based on valuations prepared by Baker Tilly and reviewed by Danske Bank [9] - Outstanding convertible loans were confirmed to total approximately DKK 13 million [10] Group 3: Remuneration and Board Elections - The remuneration for the Board of Directors for the 2025 financial year was proposed, with the Chairman receiving DKK 350,000 and Board members receiving DKK 150,000 [14] - All current Board members were re-elected, and two new members, Troels Peter Troelsen and Charlotte Pahl, were elected [16][17] - BDO Statsautoriseret Revisionsaktieselskab was re-elected as the Company's auditor [18] Group 4: Proposals and Authorizations - Three proposals from the Board were discussed, requiring different majorities for adoption, and all were approved without objections [19][20] - The chairman was authorized to file the adopted resolutions with the Danish Business Authority [21] Group 5: Company Overview - Pharma Equity Group A/S is dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S, with a focus on healthcare and innovative medical solutions [23][24]

Core Points - The Annual General Meeting of Tulikivi Corporation was held on 24 April 2025, where key decisions regarding financial statements, share issuance, and board remuneration were made [1][2]. Financial Statements and Profit Distribution - The financial statements for the financial year 2024 were approved, and the Board and Managing Director were discharged from liability [2]. - The Board of Directors was authorized to distribute funds from the reserve for invested unrestricted equity, with a maximum of EUR 0.01 per A share and EUR 0.0083 per K share [3]. Board Remuneration - Each member of the Board of Directors will receive an annual remuneration of EUR 22,000, payable in Series A shares, with shares to be purchased by 31 December 2025 [4]. - The Chair of the Board will receive an additional monthly remuneration of EUR 4,500 [5]. - Members of the Audit Committee and Nomination Committee will receive fees of EUR 350 and EUR 700 per meeting, respectively [6]. Board Composition - The number of Board members was set at seven, with six current members re-elected and one new member, Panu Paappanen, elected [7]. Auditor Appointment - KPMG Oy Ab was elected as the auditor, with Heli Tuuri as the auditor in charge [8]. Share Issuance Authorization - The Board was authorized to decide on the issuance of new shares and the company's own shares, with a maximum of 10,437,748 Series A shares and 1,536,500 Series K shares that may be issued [9][12]. - The authorization for share issuance will remain in effect until the Annual General Meeting in 2026, or until 30 June 2026, whichever comes first [13]. Board Organization - Jyrki Tähtinen was elected as Chair of the Board, with additional appointments made for the Nomination and Audit Committees [14].